Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer

John P A Ioannidis; Anastasia Polycarpou; Christos Ntais; Nicholas Pavlidis

doi:10.1016/s0959-8049(03)00571-9

Related publications

Letter2011

A Combined Epigenetic Therapy Equals the Efficacy of Conventional Chemotherapy in Refractory Advanced Non–Small Cell Lung Cancer

Manuel Rodríguez‐Paredes, Manel Esteller

Article1997

163 Second line treatment of advanced non-small-cell lung cancer after cisplatin-based chemotherapy with paclitaxel and gemcitabine

E. Papadakis, C. Kourousis, Stylianos Kakolyris, N. Androulakis, Meletios A Dimopoulos, S. Tzannes, Α. Kotsakis, N. Vardakis, K. Kalbakis, N. Meramveliotakis, Dora Hatzidaki, V. Georgoulias

Article2018

Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)

Anna Tsiara, Michalis Liontos, Μαρία Καπαρέλου, Roubini Zakopoulou, Aristotelis Bamias, Meletios A Dimopoulos

Article2018

Treating ALK-positive non-small cell lung cancer

Dimitrios C. Ziogas, Anna Tsiara, Georgios Tsironis, Maria Lykka, Michalis Liontos, Aristotelis Bamias, Meletios A Dimopoulos

Article2021

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

Jianxing He, Chunxia Su, Wenhua Liang, Shidong Xu, Lin Wu, Xiangning Fu, Xu Dong Zhang, Di Ge, Qun Chen, Weimin Mao, Lin Xu, Chun Chen, Bing Hu, Guoguang Shao, Jian Hu, Jian Zhao, Xiaoqing Liu, Zhidong Liu, Zheng Wang, Zemin Xiao, Taiqian Gong, Wen Lin, Xingya Li, Feng Ye,